The pharmacological rationale for targeting IL-17 in certain asthma phenotypes is legitimated by its involvement in the development of severity characteristics: it reduces the sensitivity to corticosteroids [15], stimulates expression of the mucin MUC5B (a marker for mucin overproduction) [16] and drives hyperresponsiveness [17]. This evidence concerns the gene MUC5AC and asthma.